Arcus Biosciences Releases New Data on Casdatifan
Arcus Biosciences announced a new analysis of efficacy and biomarker data for casdatifan, a HIF-2a inhibitor with best-in-class potential, in late-line metastatic clear cell renal cell carcinoma from the Phase 1/1b ARC-20 study. These data will be presented on February 28 at the American Society of Clinical Oncology Genitourinary Cancer Symposium. Median progression-free survival was 15.1 months, and the confirmed overall response rate, or cORR, increased to 45% for the 100mg QD tablet cohort in an updated analysis of the ARC-20 study. In a pooled analysis of all four monotherapy cohorts, casdatifan data were better on every efficacy measure evaluated relative to published data from studies with the only marketed HIF-2a inhibitor. New biomarker data demonstrated correlation between magnitude and durability of serum erythropoietin, or sEPO, suppression by casdatifan and clinical benefit, including cORR and PFS. At the time of data cut-off, no unexpected safety signals were observed, and casdatifan had an acceptable and manageable safety profile across all doses. Taiho has development and commercial rights in Japan and other countries in Asia, excluding China. Arcus Biosciences holds full rights to casdatifan everywhere else globally.
